Project will document burden of urologic disease in U.S.
The NIDDK-funded 'Urologic Diseases in America' is a broad-based, $6.9million project that will quantify the economic and human burden of urologicdiseases on the American population. In this exclusive Urology Times interview,Mark S. Litwin, MD, MPH, the study's principal investigator, outlines thescope of the project, its goals and objectives, and its relevance to practicingurologists. Dr. Litwin is professor of urology and public health at theDavid Geffen School of Medicine at UCLA and the UCLA School of Public Health.He is also a researcher at UCLA's Jonsson Comprehensive Cancer Center. Theinterview was conducted by UT Editorial Consultant Richard D. Williams,MD, professor and chairman of the department of urology at the Universityof Iowa, Iowa City.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.